CLINICAL_TRIALS
trial_result
· 2017-06-01
Clinical Trial Update: Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis [Phase 2]
Summary
Phase 2 clinical trial evaluating reslizumab to prevent post-treatment eosinophilia in loiasis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Loiasis | Phase 2 | Status: COMPLETED | Results posted: 2017-06-01